

# ASX Announcement

Medibio Limited – 9 March 2020



## Executive Appointments at Medibio to Support Growth of ilumen™

**Melbourne, Australia and Minneapolis, MN – 9th March 2020: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCPINK: MDBIF),** a mental health technology company today announces the appointment of Ms Kelly Trupkovic as Partnerships and Marketing Manager for the APAC Region and Dr Stephen Addis as a consultant, to its executive team to support and accelerate the growth of ilumen™.

Ms. Trupkovic is a people risk consultant, with over 15 years' experience gained from a range of Australian and multinational organisations within the financial services sector, specifically Group Risk and Corporate Superannuation arenas where she focused her time and efforts in key account management, sales and business development. Ms. Trupkovic is a passionate advocate for mental wellness in the corporate environment and excels at building new, comprehensive partnerships.

In her previous role at Mercer Marsh, she established and maintained new business pipelines over four specific channels: Employee Health and Benefits, Domestic Health (Private Health Insurance), Workforce Strategies and Rehabilitation/Injury Management, adhering to and adapting unique sales methodologies for each. Kelly exemplifies the ability to establish and implement sustainable business growth initiatives across new and existing markets across a variety of channels. She has demonstrated an ability to deliver on strategic people risk initiatives, whilst promoting and enhancing key strategies that are core to Medibio's business objectives. Ms. Trupkovic is a results driven sales leader who joins us to nurture and execute long-term growth strategies which will support our partner's key corporate wellness activities and objectives.

Senior Vice President, Corporate Health, Jennifer Solitario said: *"The appointment of Kelly Trupkovic signifies a very important step for Medibio as we move to increase sales and partnerships for ilumen™ across a wide range of organisations within Australia and the APAC region. Kelly's experience and relationships in the industry will be a significant advantage for Medibio."*

Dr Addis is a founding shareholder and an early contributor to the intellectual property upon which the Company was built. He is a former Head of Psychiatry at Fremantle Hospital, a large university teaching hospital in Western Australia. He has held senior clinical and managerial positions in North America, the United Kingdom and Australia which has given him first-hand knowledge of health systems internationally. He has over 20 years' experience as Principal Investigator/Investigator on pharmaceutical trials and importantly, over a decade of clinical research into the effects of mental illness upon the circadian heart rate; research that forms the basis of the Company's intellectual property.

Managing Director, Mr Claude Solitario said: *"Dr Addis will oversee the ongoing development and commercialisation of ilumen™. His support of ilumen from a scientific and medical perspective will be significant. I personally am excited to be working with Stephen again and look forward to the valuable contribution that I know he can make, given his background and experience, his knowledge of our intellectual property and importantly his insights as to how to position ilumen for commercialisation"*.

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited

# ASX Announcement

Medibio Limited – 9 March 2020



## **About Medibio Limited**

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).

### **Medibio Investor and Media Enquiries:**

Peter Taylor

NWR Communications

[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)

T: +61 (0) 412 036 231